Altria Group (MO) Earnings Date & Reports

Key Takeaways

• Altria Group is scheduled to report third-quarter (Q3) 2026 results on Thursday, October 29, 2026, before the market opens.
• Wall Street consensus calls for adjusted diluted earnings per share (EPS) of approximately $1.51, up from $1.45 in the year-ago quarter.
• Full-year 2026 guidance was narrowed to a range of $5.61 to $5.72 in adjusted diluted EPS, implying 3.5% to 5.5% growth from 2025.
• Investors will watch pricing power, cigarette shipment volumes, and the ramp of smoke-free products such as on! nicotine pouches and NJOY e-vapor.
• The stock showed a post-earnings drift of about -1.7% following its prior quarterly release, underscoring sensitivity to headline results.

Earnings Context and Why It Matters

Altria Group (MO) is the parent of Philip Morris USA, the maker of Marlboro, and a growing portfolio of smoke-free and non-nicotine products. As combustible cigarette volumes decline industry-wide, the company's earnings story increasingly hinges on its ability to raise prices and expand next-generation offerings. The Q3 2026 report arrives as management pushes on! PLUS nicotine pouches nationally and launches Marlboro Cowboy Cut to capture value-conscious smokers. For income-focused investors, Altria also matters as a high-yield dividend payer that routinely returns cash through buybacks. The quarterly print will test whether margin-driven profit growth can keep overcoming a shrinking core business.

Earnings Expectations

Analysts expect Altria to deliver adjusted diluted EPS of roughly $1.51 for Q3 2026, which would mark an increase of about 4% from the $1.45 reported in the third quarter of 2025. Consensus revenue forecasts cluster near $5.3 billion, with estimates for revenues net of excise taxes around $5.3 billion as well.

For context, Altria posted adjusted diluted EPS of $1.48 in Q2 2026, up 2.8% year over year, on net revenues that were essentially flat at $6.1 billion while revenues net of excise taxes rose 1.2% to $5.4 billion. In Q1 2026, adjusted diluted EPS climbed 7.3% to $1.32. Management has pointed to pricing gains, fewer shares outstanding, and margin expansion as the primary earnings drivers, even as cigarette shipment volumes decline.

Key metrics to watch include domestic cigarette shipment volumes, Marlboro's retail share of the premium segment, and adjusted operating companies income (OCI) margins, which the company uses to measure segment profitability. Investors will also look for any update to the narrowed full-year guidance of $5.61 to $5.72 per share.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings events like Altria's, it can surface relevant candidates across the consumer staples and tobacco sectors. Explore the AI Screener to refine your watchlist ahead of key reporting dates.

Market Reaction and Investor Sentiment

Sentiment heading into the Q3 2026 print is balanced but cautious. Altria shares have shown limited post-earnings drift since the Q2 2026 release in late July, with an estimated drift of about -1.7%, reflecting investor sensitivity to revenue misses and cigarette volume trends. The prior quarter's report, in which adjusted EPS of $1.48 came in slightly below the $1.50 consensus while revenue beat, illustrates the market's focus on both the bottom line and the trajectory of the combustible business.

Key risk factors include persistent discretionary-income pressures on adult tobacco consumers, ongoing volume declines in cigarettes, and regulatory or litigation developments. Conversely, disciplined pricing, share repurchases, and smoke-free momentum provide a potential cushion. Analysts will be watching whether Altria can once again convert pricing strength into EPS growth despite softer volumes.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should monitor several themes that will shape Altria's trajectory through the rest of 2026 and into 2027. The first is the national expansion of on! PLUS nicotine pouches, which represents the company's push into the fast-growing oral nicotine pouch category. Sustained shipment growth here could help offset ongoing weakness in moist smokeless tobacco and cigarettes.

The second area is the combustible business itself. Marlboro Cowboy Cut is aimed at value-conscious smokers as trade-down activity persists, and its reception could influence both volume and the company's pricing mix. Management has consistently leaned on pricing and margin discipline, so adjusted OCI margins in the smokeable products segment will remain a closely watched profitability gauge.

Finally, capital returns and guidance remain central to the investment case. Altria has targeted mid-single-digit annual dividend growth and continues to repurchase shares, which supports per-share earnings. Any revision to the full-year 2026 adjusted diluted EPS range of $5.61 to $5.72 will be a key signal for the fourth quarter. Regulatory developments, including the company's planned NJOY ACE e-vapor reentry pending clearance, also warrant attention as potential catalysts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations